Physician profile
Thomas A Biondo
NPI 1649229519
$10,460.78
in general payments reported to CMS, 2019-2025
46 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,412 · 2020: $568 · 2021: $916 · 2022: $1,435 · 2023: $1,709 · 2024: $1,715 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,036 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,036.23 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,147.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,143.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $942.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $908.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $823.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $712.70 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $695.30 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $459.97 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.55 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $277.16 | 2019-2024 | Veozah |
| Grifols USA, LLC | $272.53 | 2019-2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $210.84 | 2019-2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $208.58 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $192.01 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.01 | 2019-2025 | Xifaxan, Trulance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Biondo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.